Copyright Reports & Markets. All rights reserved.

Global AI in Respiratory Diseases Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of AI in Respiratory Diseases by Type
    • 1.3.1 Overview: Global AI in Respiratory Diseases Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global AI in Respiratory Diseases Consumption Value Market Share by Type in 2025
    • 1.3.3 Pulmonary Infection
    • 1.3.4 MRI
    • 1.3.5 CT Scan
  • 1.4 Global AI in Respiratory Diseases Market by Application
    • 1.4.1 Overview: Global AI in Respiratory Diseases Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Diagnostic Centers
    • 1.4.4 Ambulatory Surgical Centers
    • 1.4.5 Others
  • 1.5 Global AI in Respiratory Diseases Market Size & Forecast
  • 1.6 Global AI in Respiratory Diseases Market Size and Forecast by Region
    • 1.6.1 Global AI in Respiratory Diseases Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global AI in Respiratory Diseases Market Size by Region, (2021-2032)
    • 1.6.3 North America AI in Respiratory Diseases Market Size and Prospect (2021-2032)
    • 1.6.4 Europe AI in Respiratory Diseases Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific AI in Respiratory Diseases Market Size and Prospect (2021-2032)
    • 1.6.6 South America AI in Respiratory Diseases Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa AI in Respiratory Diseases Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 ArtiQ
    • 2.1.1 ArtiQ Details
    • 2.1.2 ArtiQ Major Business
    • 2.1.3 ArtiQ AI in Respiratory Diseases Product and Solutions
    • 2.1.4 ArtiQ AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 ArtiQ Recent Developments and Future Plans
  • 2.2 Philips Healthcare
    • 2.2.1 Philips Healthcare Details
    • 2.2.2 Philips Healthcare Major Business
    • 2.2.3 Philips Healthcare AI in Respiratory Diseases Product and Solutions
    • 2.2.4 Philips Healthcare AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Philips Healthcare Recent Developments and Future Plans
  • 2.3 GE Healthcare
    • 2.3.1 GE Healthcare Details
    • 2.3.2 GE Healthcare Major Business
    • 2.3.3 GE Healthcare AI in Respiratory Diseases Product and Solutions
    • 2.3.4 GE Healthcare AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 GE Healthcare Recent Developments and Future Plans
  • 2.4 Siemens Healthineers
    • 2.4.1 Siemens Healthineers Details
    • 2.4.2 Siemens Healthineers Major Business
    • 2.4.3 Siemens Healthineers AI in Respiratory Diseases Product and Solutions
    • 2.4.4 Siemens Healthineers AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Siemens Healthineers Recent Developments and Future Plans
  • 2.5 Swaasa AI
    • 2.5.1 Swaasa AI Details
    • 2.5.2 Swaasa AI Major Business
    • 2.5.3 Swaasa AI AI in Respiratory Diseases Product and Solutions
    • 2.5.4 Swaasa AI AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Swaasa AI Recent Developments and Future Plans
  • 2.6 THIRONA
    • 2.6.1 THIRONA Details
    • 2.6.2 THIRONA Major Business
    • 2.6.3 THIRONA AI in Respiratory Diseases Product and Solutions
    • 2.6.4 THIRONA AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 THIRONA Recent Developments and Future Plans
  • 2.7 DeepMind Health
    • 2.7.1 DeepMind Health Details
    • 2.7.2 DeepMind Health Major Business
    • 2.7.3 DeepMind Health AI in Respiratory Diseases Product and Solutions
    • 2.7.4 DeepMind Health AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 DeepMind Health Recent Developments and Future Plans
  • 2.8 Verily
    • 2.8.1 Verily Details
    • 2.8.2 Verily Major Business
    • 2.8.3 Verily AI in Respiratory Diseases Product and Solutions
    • 2.8.4 Verily AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Verily Recent Developments and Future Plans
  • 2.9 VIDA Diagnostics Inc
    • 2.9.1 VIDA Diagnostics Inc Details
    • 2.9.2 VIDA Diagnostics Inc Major Business
    • 2.9.3 VIDA Diagnostics Inc AI in Respiratory Diseases Product and Solutions
    • 2.9.4 VIDA Diagnostics Inc AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 VIDA Diagnostics Inc Recent Developments and Future Plans
  • 2.10 Icometrix
    • 2.10.1 Icometrix Details
    • 2.10.2 Icometrix Major Business
    • 2.10.3 Icometrix AI in Respiratory Diseases Product and Solutions
    • 2.10.4 Icometrix AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Icometrix Recent Developments and Future Plans
  • 2.11 Infervision
    • 2.11.1 Infervision Details
    • 2.11.2 Infervision Major Business
    • 2.11.3 Infervision AI in Respiratory Diseases Product and Solutions
    • 2.11.4 Infervision AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Infervision Recent Developments and Future Plans
  • 2.12 PneumoWave
    • 2.12.1 PneumoWave Details
    • 2.12.2 PneumoWave Major Business
    • 2.12.3 PneumoWave AI in Respiratory Diseases Product and Solutions
    • 2.12.4 PneumoWave AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 PneumoWave Recent Developments and Future Plans
  • 2.13 Respiray
    • 2.13.1 Respiray Details
    • 2.13.2 Respiray Major Business
    • 2.13.3 Respiray AI in Respiratory Diseases Product and Solutions
    • 2.13.4 Respiray AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Respiray Recent Developments and Future Plans
  • 2.14 Dectrocel Healthcare
    • 2.14.1 Dectrocel Healthcare Details
    • 2.14.2 Dectrocel Healthcare Major Business
    • 2.14.3 Dectrocel Healthcare AI in Respiratory Diseases Product and Solutions
    • 2.14.4 Dectrocel Healthcare AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Dectrocel Healthcare Recent Developments and Future Plans
  • 2.15 Zynnon
    • 2.15.1 Zynnon Details
    • 2.15.2 Zynnon Major Business
    • 2.15.3 Zynnon AI in Respiratory Diseases Product and Solutions
    • 2.15.4 Zynnon AI in Respiratory Diseases Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Zynnon Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global AI in Respiratory Diseases Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of AI in Respiratory Diseases by Company Revenue
    • 3.2.2 Top 3 AI in Respiratory Diseases Players Market Share in 2025
    • 3.2.3 Top 6 AI in Respiratory Diseases Players Market Share in 2025
  • 3.3 AI in Respiratory Diseases Market: Overall Company Footprint Analysis
    • 3.3.1 AI in Respiratory Diseases Market: Region Footprint
    • 3.3.2 AI in Respiratory Diseases Market: Company Product Type Footprint
    • 3.3.3 AI in Respiratory Diseases Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global AI in Respiratory Diseases Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global AI in Respiratory Diseases Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global AI in Respiratory Diseases Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global AI in Respiratory Diseases Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America AI in Respiratory Diseases Consumption Value by Type (2021-2032)
  • 6.2 North America AI in Respiratory Diseases Market Size by Application (2021-2032)
  • 6.3 North America AI in Respiratory Diseases Market Size by Country
    • 6.3.1 North America AI in Respiratory Diseases Consumption Value by Country (2021-2032)
    • 6.3.2 United States AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 6.3.3 Canada AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico AI in Respiratory Diseases Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe AI in Respiratory Diseases Consumption Value by Type (2021-2032)
  • 7.2 Europe AI in Respiratory Diseases Consumption Value by Application (2021-2032)
  • 7.3 Europe AI in Respiratory Diseases Market Size by Country
    • 7.3.1 Europe AI in Respiratory Diseases Consumption Value by Country (2021-2032)
    • 7.3.2 Germany AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 7.3.3 France AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 7.3.5 Russia AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 7.3.6 Italy AI in Respiratory Diseases Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific AI in Respiratory Diseases Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific AI in Respiratory Diseases Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific AI in Respiratory Diseases Market Size by Region
    • 8.3.1 Asia-Pacific AI in Respiratory Diseases Consumption Value by Region (2021-2032)
    • 8.3.2 China AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 8.3.3 Japan AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 8.3.5 India AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 8.3.7 Australia AI in Respiratory Diseases Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America AI in Respiratory Diseases Consumption Value by Type (2021-2032)
  • 9.2 South America AI in Respiratory Diseases Consumption Value by Application (2021-2032)
  • 9.3 South America AI in Respiratory Diseases Market Size by Country
    • 9.3.1 South America AI in Respiratory Diseases Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina AI in Respiratory Diseases Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa AI in Respiratory Diseases Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa AI in Respiratory Diseases Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa AI in Respiratory Diseases Market Size by Country
    • 10.3.1 Middle East & Africa AI in Respiratory Diseases Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia AI in Respiratory Diseases Market Size and Forecast (2021-2032)
    • 10.3.4 UAE AI in Respiratory Diseases Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 AI in Respiratory Diseases Market Drivers
  • 11.2 AI in Respiratory Diseases Market Restraints
  • 11.3 AI in Respiratory Diseases Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 AI in Respiratory Diseases Industry Chain
  • 12.2 AI in Respiratory Diseases Upstream Analysis
  • 12.3 AI in Respiratory Diseases Midstream Analysis
  • 12.4 AI in Respiratory Diseases Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global AI in Respiratory Diseases market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global AI in Respiratory Diseases market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global AI in Respiratory Diseases market size and forecasts, in consumption value ($ Million), 2021-2032
    Global AI in Respiratory Diseases market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global AI in Respiratory Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global AI in Respiratory Diseases market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for AI in Respiratory Diseases
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global AI in Respiratory Diseases market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ArtiQ, Philips Healthcare, GE Healthcare, Siemens Healthineers, Swaasa AI, THIRONA, DeepMind Health, Verily, VIDA Diagnostics Inc, Icometrix, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    AI in Respiratory Diseases market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Pulmonary Infection
    MRI
    CT Scan
    Market segment by Application
    Hospital
    Diagnostic Centers
    Ambulatory Surgical Centers
    Others
    Market segment by players, this report covers
    ArtiQ
    Philips Healthcare
    GE Healthcare
    Siemens Healthineers
    Swaasa AI
    THIRONA
    DeepMind Health
    Verily
    VIDA Diagnostics Inc
    Icometrix
    Infervision
    PneumoWave
    Respiray
    Dectrocel Healthcare
    Zynnon
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe AI in Respiratory Diseases product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of AI in Respiratory Diseases, with revenue, gross margin, and global market share of AI in Respiratory Diseases from 2021 to 2026.
    Chapter 3, the AI in Respiratory Diseases competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and AI in Respiratory Diseases market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of AI in Respiratory Diseases.
    Chapter 13, to describe AI in Respiratory Diseases research findings and conclusion.

    Buy now